CIRCULATING PRIMITIVE STEM-CELLS IN PAROXYSMAL-NOCTURNAL HEMOGLOBINURIA (PNH) ARE PREDOMINANTLY NORMAL IN PHENOTYPE BUT GRANULOCYTE-COLONY-STIMULATING FACTOR TREATMENT MOBILIZES MAINLY PNH STEM-CELLS
Rj. Johnson et al., CIRCULATING PRIMITIVE STEM-CELLS IN PAROXYSMAL-NOCTURNAL HEMOGLOBINURIA (PNH) ARE PREDOMINANTLY NORMAL IN PHENOTYPE BUT GRANULOCYTE-COLONY-STIMULATING FACTOR TREATMENT MOBILIZES MAINLY PNH STEM-CELLS, Blood, 91(12), 1998, pp. 4504-4508
Paroxysmal nocturnal hemoglobinuria (PNH) is an acquired hemolytic ane
mia resulting from a somatic mutation in a hemopoietic stem cell. In m
ost cases of hemolytic PNH, the majority of the marrow cells are deriv
ed from the PNH clone. Recent evidence has indicated, however, that th
e majority of the most primitive peripheral blood stem cells (PBSCs) i
n PNH appear to be of normal phenotype. This has led to tentative sugg
estions that normal PBSCs could be collected and used for autologous t
ransplantation. We have investigated this possibility in four PNH pati
ents by treating them with granulocyte colony-stimulating factor (G-CS
F) in an attempt to mobilize normal progenitors. The expression of gly
cosylphosphatidylinositol (GPI)-linked proteins was analyzed by flow c
ytometry on mature neutrophils, late stem cells (CD34(+)/CD38(+)), and
primitive stem cells (CD34(+)/CD38(-)). The phenotyping and stem cell
quantitation was performed in steady-state blood and post-G CSF admin
istration. The most primitive PBSCs (CD34(+)/CD38(-)) were almost all
normal before G-CSF treatment, even when the patients' neutrophils wer
e mainly PNH. However, after G-CSF, the cells that were mobilized into
the peripheral blood were of a similar phenotype to the mature neutro
phils, ie, mainly PNH. it is possible that PNH-stem cells are preferen
tially destroyed by complement in the peripheral blood leaving only no
rmal cells in the circulation. After G-CSF, the PNH cells in the marro
w are released into the blood. Our findings suggest that it would be d
ifficult to collect sufficient numbers of normal stem cells for autolo
gous transplantation. (C) 1998 by The American Society of Hematology.